Final Practicum Oral Board Flashcards

1
Q

Monocryl Plus (Braided or Monafilament)

A

Synthetic Absorbable

Monofilament

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Monocryl Absorption Rate

A

91-119 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Monocryl Breaking Strength Retention:

A

Undyed= 50-60% at week 1, 20-30% at week 2

Dyed= 60-70% at week 1, 30-40% at week 2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Monocryl Indications for use

A

(LUVPBS)

Ligation
Uterus
Vaginal Cuff
Peritoneum
Bowel
Skin Repairs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Vicryl Plus (Braided or Monofilament)

A

Synthetic Absorbable- Braided

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Vicryl Plus Absorption rate:

A

56-70 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Vicryl Breaking strength retention

A

75% at 2 weeks, 50% at 3 weeks, 25% at 4 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Vicryl Indications for use:

A

LGOB

Ligation
General Closure
Orthopedic Surgery
Bowel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

PDS Plus (Braided or Monofilament)

A

Synthetic absorbable Monofilament

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

PDS Absorption rate:

A

182-238 Days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

PDS breaking strength retention

A

4-0 & smaller- 60% at 2 weeks, 40% at 4 weeks, 35% at 6 weeks

3-0 & Larger- 80% at 2 weeks, 70% at 4 weeks, 60% at 6 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

PDS indications for use

A

FBPOP

Fascial Closure
Blood vessel anastomosis
Pediatric cardiovascular and Ophthalmic procedures except for in contact with the cornea or sclera
Orthopedic
Patients with compromised wound healing conditions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Bacteria for Monocryl, Vicryl, PDS

A

Monocryl and PDS: Staph A, Staph E, MRSA, MRSE, E. Coli, K. Pneumoniae, E. Cloacae

Vicryl: Staph A, Staph E, MRSA, MRSE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe Qualities of Prolene Suture, and types of procedures?

A

Qualities: Synthetic, Monofilament, Non-Absorbable

Procedures- Cardiovascular (CABG), Ophthalmic, Neurological

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe Key features of everpoint:

A

Made of unique tungsten-rhenium coating that allows that for more penetration, durability, strength, and stiffness

Compared to traditional steel needles:
70% Sharper
38% Stronger
121% more bend resistant

Non magnetic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the Key Features and benefits of Dermabond PRINEO?

A

Microbial barrier: proven to be 99% effective through 72 hours in vitro against most commonly associated with SSI, including: pseudomonas aeurginosa, esherichia coli, enterococcus faecium, staph A, staph E

Dermabond PRINEO is 40% stronger than a 4-0 Monocryl suture, and 33% stronger than skin staples

At the time of removal, PRINEO is associated with less pain than other wound closure devices

17
Q

Define the value proposition for STRATAFIX

A

Security: provides strength and security of an interrupted closure without the knots

Efficiency: no knots, no need for an assistant following the suture, no need to hold/maintain tension after each pass, and potentially less time under anesthesia

Consistency- allows for easier management of tension and gives the ability to control approximation providing for a more consistent closure

18
Q

Describe the key differences between STRATAFIX symmetric and VLOC 180?

A

Superior tissue holding strength

Antibacterial properties

Appropriate for use in fascia

Superior needle performance

Extended tensile wound healing strength

19
Q

Surgicel Bleeding Situation

A

Continuous oozing is a situation that will not stop with compression or single packing, and it is more time consuming than it is difficult

20
Q

Surgicel Mechanism of action

A

Biologic: once moistened, the cellulose breaks down, releasing glucuronic acid which has a pH of 2.5, when it comes to contact with blood which has a pH of 7.4 decreases the blood’s to 4.4 which aids in vasoconstriction, the acidity of pH also gives bactericidal properties

Mechanic- as the blood continues to be absorbed, it swells into a gelatinous mass which serves as a matrix for platelet adhesion and aggregation

21
Q

Surgicel Indication

A

Indicated for use adjunctively to control or assist with capillary, venous, or small arterial hemorrhages when ligation or conventional methods are ineffective or impractical

22
Q

Describe why SURGICEL is bactericidal against the pathogens most commonly associated with SSI’s:

A

The normal condition of blood will start with a blood pH of 7.4, which is a pH level that allows bacteria to proliferate

Once the moisture reaches SURGICEL the cellulose begins to break down and that initiates the release of glucoronic acid

With the release of glucuronic acid and the interaction with the blood pH, it drops the pH to 4.4 which gives it bactericidal properties so that bacteria can’t proliferate

23
Q

What selling points does SURGICEL powder have over ARISTA AH?

A

89% faster to hemostasis

Induces vasoconstriction, which provides matrix sites to aid in platelet adhesion and aggregation

Surgicel powder penetrates the source of the bleed by having large particles sink to the source of the bleed, whereas ARISTA floats on the surface of the blood

Surgicel powder forms a more durable clot that maintains hemostasis even after being irrigated

Powder is the #1 most trusted adjunctive hemostat

Demonstrated bactericidal against MRSA, MRSE, PRSP, VRE, E. COLI

24
Q

SURGIFLO Mechanism of action

A

Mechanical: provides a matrix for platelet adherence, accelerating the formation of the platelet plug

Biological: when used with thrombin, thrombin converts fibrinogen into fibrin, aiding in fibrin clot formation

25
SURGIFLO Indication
Used adjunctively in surgical procedures to assist in the control of capillary, venous, or small arterial hemorrhages when ligation or other conventional methods of control are ineffective or impractical (except for ophthalmic)
26
SURGIFLO Bleeding situation
Difficult to access is when it occurs in tight and irregular spaces and you cannot see the exact source of the bleed, there is concern accessing a tight space will cause more harm
27
VISTASEAL mechanism of action
Initiates fibrin clot formation through the reaction of thrombin and fibrinogen to form a fibrin clot
28
VISTASEAL Indications
Used as an adjunct to hemostasis in mild to moderate bleeding in adults undergoing surgery when control of bleeding by standard surgical techniques is ineffective or impractical (effective in heparinized patients)
29
VISTASEAL Bleeding situation
Potential re-bleeding risk is a situation that can be addressed intraoperativley, but could later develop into more serious complications, especially in high risk patients
30
EVARREST mechanism of action
Achieves hemostasis when fibrin clot integrates with patch component and adheres to the wound surface, this then provides a physical barrier and achieves hemostasis
31
EVARREST indications
Indicated for use with manual compression as an adjunct to hemostasis in adult patients undergoing surgery, when control of bleeding by conventional methods is impractical or ineffective
32
EVARREST contraindications
(TOPICAL USE ONLY) do not use to treat bleeding from large defects in arteries or veins ( not to be used in place of suture, ligature, cautery) Do not apply intravascularly Do not apply to patients known to have anaphylactic reactions to human blood products
33
EVARREST bleeding situation
Situation where bleeding is accessible, but is likely to be more than routine and likely to be resistant to conventional methods and could take numerous attempts to stop
34
5 steps of hemostasic cascade
Vessel injury Vasoconstriction Platelet plug formation Fibrin clot formation Fibrinolysis
35
Monocryl polymer
Poligelcaprone 25
36
Vicryl polymer
Polyglactin 910
37
PDS Polymer
Polydiaxonone